Patents by Inventor Yan-ping Yang
Yan-ping Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5962430Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases (caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.Type: GrantFiled: February 18, 1997Date of Patent: October 5, 1999Inventors: Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein
-
Patent number: 5939297Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.Type: GrantFiled: August 26, 1994Date of Patent: August 17, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein
-
Patent number: 5935573Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.Type: GrantFiled: June 7, 1995Date of Patent: August 10, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein
-
Patent number: 5922562Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: November 8, 1994Date of Patent: July 13, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5922323Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: June 7, 1995Date of Patent: July 13, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5922841Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: June 7, 1995Date of Patent: July 13, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5869302Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.Type: GrantFiled: June 7, 1995Date of Patent: February 9, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein
-
Patent number: 5708149Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: June 7, 1995Date of Patent: January 13, 1998Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5681570Abstract: Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a Streptococcus strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from Streptococcus pneumoniae are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than Streptococcus also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the Streptococcus strain and preferably also the Haemophilus strain.Type: GrantFiled: January 12, 1995Date of Patent: October 28, 1997Assignee: Connaught Laboratories LimitedInventors: Yan-ping Yang, Ali Kandil, Lucy Gisonni, Raafat Emil Fahmy Fahim, Michel Henri Klein
-
Patent number: 5665353Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.Type: GrantFiled: June 7, 1995Date of Patent: September 9, 1997Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein
-
Patent number: 5656436Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.Type: GrantFiled: June 7, 1995Date of Patent: August 12, 1997Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein
-
Patent number: 5506139Abstract: An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.Type: GrantFiled: July 21, 1994Date of Patent: April 9, 1996Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Pele Chong, Raymond P. Oomen, Michel H. Klein